DS Healthcare Group to launch oral tablet in multi-billion-dollar hair-loss
Logical extension of company's industry-leading topical line
Pompano Beach, Dec. 4, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group
Inc.(NASDAQ:DSKX), a leading developer of personal care products, announced
that it has developed and will launch an over-the-counter neutraceutical
tablet to combat premature hair thinning and improve healthy hair growth. Sold
under the DS Laboratories brand, the tablet will complement and extend the
company's industry-leading topical treatments, which promote longer, stronger,
The new DS Laboratories tablet will launch in Mexico during the first quarter
of 2014. It will expand worldwide through the company's growing network of
foreign markets. DS Laboratories products already sell in more than 15
countries as part of a rapid global expansion.
The new oral supplement employs a novel approach within the thinning-hair
category -- complex peptides with potent antioxidants -- to maximize efficacy
and potency. This formula results from ongoing clinical research at DS
Healthcare Group on hair loss and related conditions.
"We've developed our own proprietary tablet, which contains a unique
composition of ingredients, to achieve a real breakthrough in neutraceutical
research," stated DS Healthcare President and CEO Daniel Khesin.
"Similar oral supplements already enjoy significant revenue in overseas
markets where we have strong distribution. But none of the products we tested
provided any real benefit to consumers. We have set out to improve this
category, and we are very pleased with the outcome. Retailers worldwide have
expressed great interest in our new tablet based on existing demand for
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development and distribution of topical
therapies for personal care, including what management believes is the world's
most effective topical treatments for hair loss. Its products are sold through
a network of salons, pharmacies, online retailers, specialty retailers, and
select department stores. Its brands include DS Laboratories
(www.DSLaboratories.com), Sigma Skin (www.SigmaSkin.com), Polaris Research
Laboratories (www.PolarisResearchLabs.com), The Pure Guild
(www.ThePureGuild.com), and Nutra Origin (www.NutraOrigin.com).
Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or strategies, and
are generally preceded by words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ
materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products,
intense competition, and additional risks factors as discussed in reports
filed by the company with the Securities and Exchange Commission, which are
available at http://www.sec.gov.
DS Healthcare Group,Inc.
Press spacebar to pause and continue. Press esc to stop.